Pulsed Field Ablation of Atrial Fibrillation: CENTAURI Versus FARAPULSE

Brief summary (registry, in English)

The aim of this study is to compare the efficacy of two commercially available pulsed field ablation (PFA) systems for catheter ablation of atrial fibrillation. Patients are randomized 1:1 to point-by-point PFA using the CENTAURI PEF system with 3D electroanatomical mapping, or to single-shot PFA using the FARAPULSE pentaspline catheter guided by fluoroscopy and intracardiac echocardiography. The primary endpoint is freedom from documented atrial arrhythmia recurrence between 3 and 12 months after ablation.

What you commit to

• Study type: Interventional
• Participants enrolled: 325
• From 17 May 2024 to the primary completion date, 5 Oct 2026
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.